Business Wire9h
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives itch and is involved in inflammation and skin barrier ...
Galderma's Nemluvio® (Nemolizumab) Approved In The European Union For Moderate-To-Severe Atopic Dermatitis And Prurigo N...
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...
Newsmaker | Down in the dumps in Odisha, Congress bets on SC face, old streetfighter Bhakta Charan Das
Earlier, party picked an ST leader for CLP position. However, Das faces an uphill battle as PCC chief in a state where ...